Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. For over a decade, the therapeutic landscape was dominated by tyrosine kinase inhibitors such as sorafenib and lenvatinib, with limited success. There has been a dramatic shift with the introduction of immune checkpoint inhibitors for the management of advanced disease. HCC develops in the background of a chronically inflamed and immunosuppressive hepatic microenvironment, making immunotherapy a biologically compelling option. Regimens such as IMbrave150 and HIMALAYA have shown significant improvements in overall survival (OS), but only a small fraction of patients get durable long-term benefit. Here, we dissect the latest dual immunotherapy regimen, nivolumab and ipilimumab, which showed an OS benefit versus lenvatinib and sorafenib in advanced unresectable HCC. The reported OS benefit is one of the highest so far in advanced HCC, but the study comes with its own caveats. Several challenges include the identification of predictive biomarkers, the management of immune-related toxicities, and the optimization of sequencing strategies. Through this brief commentary, we address key areas like selection of optimal patients with special focus on baseline liver function, comparison with other approved immunotherapy combinations, and toxicity management which is of utmost importance before this regimen can be primed for daily use. With a plethora of treatment options available, cost, infrastructure, and access become as important as translating trial endpoints into real-world practice.
Santhosh et al. (Mon,) studied this question.